Workflow
募集资金使用调整
icon
Search documents
浙江今飞凯达轮毂股份有限公司关于召开2025年第二次临时股东大会的通知
Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on September 29, 2025, at 14:30 [3][10] - The meeting will combine on-site and online voting methods, allowing shareholders to participate through the Shenzhen Stock Exchange trading system and internet voting system [4][5] - The record date for shareholders eligible to attend the meeting is September 23, 2025 [6][7] Group 2 - The board of directors approved a proposal to apply for an increase in the comprehensive credit limit of up to RMB 60 million [29][48] - The company plans to use the funds for normal operational needs, including various financial instruments such as bank loans and bills [48] - The board also approved the adjustment of the investment scale for a specific fundraising project, which will now be concluded, and the remaining funds will be permanently supplemented into working capital [39][43]
美迪西: 美迪西:2025年第二次临时股东大会会议资料
Zheng Quan Zhi Xing· 2025-09-05 10:17
Core Viewpoint - Shanghai Medicilon Biomedicine Co., Ltd. plans to terminate certain fundraising projects and redirect the remaining funds to new projects, permanently supplement working capital, and continue to store funds in a special account [1][27]. Group 1: Fundraising and Project Termination - The total amount raised by the company as of August 4, 2023, is RMB 1 billion, with a net amount of RMB 985.29 million after deducting fees [7][10]. - The terminated project is the "North Shanghai Biomedicine R&D Innovation Industrial Base Project," which was intended to enhance drug discovery capabilities but is no longer aligned with market demands [11][12]. - The remaining funds of RMB 289.90 million will be allocated as follows: RMB 40 million for increasing capital in MEDICILON USA CORP, RMB 160 million for working capital, and RMB 89.90 million will remain in the special account [12][13]. Group 2: New Project Overview - The new project involves establishing an "Overseas Marketing and R&D Center" in the U.S. to enhance the company's international presence and service capabilities [13][20]. - The project aims to leverage existing overseas sales and R&D teams to expand the company's market influence and improve customer service efficiency [13][19]. - The company has already established a 2,000 square meter R&D office in Boston, which will serve as a strategic hub for this initiative [20][22]. Group 3: Industry Context and Growth Potential - The global pharmaceutical market is expected to grow steadily, driven by increasing R&D investments, with global R&D spending projected to rise from USD 260.6 billion in 2023 to USD 359.2 billion by 2028, reflecting a CAGR of approximately 6.6% [16][17]. - The CRO (Contract Research Organization) industry is experiencing growth, with increasing demand for outsourced R&D services, which is expected to enhance the market penetration of CROs from 49.2% in 2023 to 58.2% by 2028 [20][21]. - The domestic CRO industry is evolving rapidly, with companies actively seeking to expand internationally and improve their service capabilities to meet global standards [17][22].
金田股份: 金田股份第九届监事会第四次会议决议公告
Zheng Quan Zhi Xing· 2025-09-01 10:20
Meeting Details - The fourth meeting of the ninth Supervisory Board of Ningbo Jintian Copper Industry (Group) Co., Ltd. was held on August 29, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1]. Proposal Review - The Supervisory Board approved the proposal to change part of the fundraising investment projects, specifically altering the original project of "annual production of 70,000 tons of precision copper alloy bars" to "annual production of 10,000 tons of double-zero grade ultra-fine copper conductors" and "450 copper alloy strip production line renovation and upgrade project" [1][2]. - The change involves a total fundraising amount of RMB 266.8593 million, accounting for 18.47% of the total net fundraising amount from the "Jintian Convertible Bonds" [1]. Fund Utilization Plan - The new projects will be implemented by the company's wholly-owned subsidiary, Ningbo Jintian High Conductivity New Materials Co., Ltd. The company plans to provide interest-free loans to the project implementer for the "annual production of 10,000 tons of double-zero grade ultra-fine copper conductors," with a total amount not exceeding RMB 134.8593 million [2]. - The Supervisory Board believes that the changes are necessary adjustments based on the fundraising project situation and the company's operational development plan, which will enhance the efficiency of fundraising utilization [2]. Voting Results - The proposal received unanimous approval with 3 votes in favor, 0 against, and 0 abstentions, and it will be submitted to the shareholders' meeting for further review [3].
英诺特: 华泰联合证券有限责任公司关于北京英诺特生物技术股份有限公司使用部分节余募集资金用于其他募投项目及募投项目延期的核查意见
Zheng Quan Zhi Xing· 2025-08-29 17:34
Core Viewpoint - The company plans to use part of the surplus raised funds for other investment projects and to postpone certain investment projects, which aligns with its strategic development and aims to enhance the efficiency of fund utilization [1][10][11]. Fundraising Basic Situation - The company raised a net amount of RMB 800.48 million from its initial public offering of 34,020,000 shares, with all funds accounted for and managed in a dedicated account [1][2]. - The funds were subject to strict regulatory oversight as per relevant guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange [1][10]. Investment Project Situation - Due to the net amount raised being lower than initially planned, the company adjusted the investment amounts for its projects to ensure efficient use of funds [2][5]. - The company has terminated certain projects, including the "In Vitro Diagnostic Product R&D and Industrialization Project (Phase I)" as of April 2024, and has made adjustments to other projects [2][5][9]. Use of Surplus Funds - The company intends to allocate RMB 60 million of the surplus funds towards the "In Vitro Diagnostic Product R&D Project," focusing on international market expansion and collaboration with Quanterix Corporation for advanced detection technologies [5][9]. - The surplus funds will also support the development of products for the EU IVDR and US FDA markets, enhancing the company's competitive position [5][9]. Project Postponement - The timeline for the "In Vitro Diagnostic Product R&D Project" has been extended from October 2025 to April 2027 to accommodate the current progress and ensure effective fund utilization [9][10]. Impact on the Company - The adjustments made in the use of surplus funds and project timelines are expected to optimize resource allocation and enhance operational efficiency without adversely affecting the company's core business [9][10]. Review and Decision Procedures - The company’s board and supervisory committee have approved the use of surplus funds, which will be submitted for shareholder approval, ensuring compliance with regulatory requirements [10][11].
英诺特: 关于使用部分节余募集资金用于其他募投项目及募投项目延期的公告
Zheng Quan Zhi Xing· 2025-08-29 17:25
证券代码:688253 证券简称:英诺特 公告编号:2025-039 (大信验字[2022]第 34-00009 号)。公 司依照规定对募集资金采取了专户存储管理,并与保荐机构华泰联合及存放募集 资金的商业银行签署了募集资金专户存储监管协议。具体情况详见公司于 2022 年 7 月 27 日在上海证券交易所网站(www.sse.com.cn)披露的《北京英诺特生 物技术股份有限公司首次公开发行股票科创板上市公告书》。 北京英诺特生物技术股份有限公司 关于使用部分节余募集资金用于其他募投项目及募 投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 北京英诺特生物技术股份有限公司(以下简称"公司")于 2025 年 8 月 27 日召开第二届董事会第十次会议、第二届监事会第十次会议,审议通过了《关于 使用部分节余募集资金用于其他募投项目及募投项目延期的议案》,同意公司使 用部分节余募集资金投资于更为适合公司当前需求的"体外诊断产品研发项目"; 同意公司将"体外诊断产品研发项目"达到预定可使用状态的 ...
金凯生科: 中信建投证券股份有限公司关于金凯(辽宁)生命科技股份有限公司部分募投项目由向子公司借款实施变更为向子公司增资实施并使用自有资金向子公司增资的核查意见
Zheng Quan Zhi Xing· 2025-08-22 16:16
Summary of Key Points Core Viewpoint - The company has decided to change the funding method for certain investment projects from providing loans to its subsidiary to increasing capital in the subsidiary, utilizing its own funds for this purpose [1][7][10]. Group 1: Fundraising Overview - The company raised a total of RMB 1,216,511,427.60 through its initial public offering, with a net amount of RMB 1,110,744,306.58 after deducting issuance costs [1][5]. - The funds were deposited into a special account approved by the company's board of directors, and a tripartite supervision agreement was signed with the sponsor and the commercial bank [1][8]. Group 2: Investment Project Details - The net amount raised will be allocated to various investment projects, including a high-end pharmaceutical product project and a pharmaceutical intermediate project [5][6]. - The company plans to invest RMB 43,886.66 million in the pharmaceutical intermediate project, with a portion of this amount being changed from a loan to a capital increase [6][7]. Group 3: Capital Increase Implementation - The company will increase its investment in its wholly-owned subsidiary, Jin Kai Pharmaceutical, by RMB 32,886.66 million and an additional RMB 1,913.34 million from its own funds [6][7]. - Following this capital increase, the registered capital of Jin Kai Pharmaceutical will rise from RMB 15,000.00 million to RMB 49,800.00 million [6][7]. Group 4: Management and Oversight - The company has established a special account for the management of raised funds and will adhere to relevant regulations to ensure the safety of these funds [8][10]. - The board of directors and the supervisory board have both approved the change in funding method, affirming that it aligns with legal requirements and benefits the company's long-term development [10][11].
莱茵生物: 第七届监事会第五次会议决议公告
Zheng Quan Zhi Xing· 2025-08-21 12:18
桂林莱茵生物科技股份有限公司 证券代码:002166 证券简称:莱茵生物 公告编号:2025-043 桂林莱茵生物科技股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 桂林莱茵生物科技股份有限公司(以下简称"公司")关于召开公司第七届 监事会第五次会议的通知于 2025 年 8 月 17 日以短信、即时通讯工具及电子邮件 的方式发出,会议于 2025 年 8 月 20 日上午 11:30 以通讯方式召开。会议应亲自 出席监事 3 人,实亲自出席监事 3 人,全体高管列席了会议,会议由监事会主席 李元元先生主持,会议的召开符合《中华人民共和国公司法》 (以下简称"《公司 法》")和《公司章程》的规定,会议合法有效。 监事会认为,本次缩减部分募投项目的投资规模、结项募投项目并将节余募 集资金永久补充流动资金是基于目前公司实际情况及合理使用募集资金所作出 的决策。公司将节余的募集资金及利息永久补充流动资金,有利于提高募集资金 使用效率,降低公司财务成本,符合公司及全体股东的利益,不存在损害公司和 股东尤其是中小股东的合法权益的情形 ...
麦加芯彩: 瑞银证券有限责任公司关于麦加芯彩新材料科技(上海)股份有限公司变更部分募投项目实施方式并调整内部投资结构的核查意见
Zheng Quan Zhi Xing· 2025-08-21 12:18
Core Viewpoint - The company, Megachip New Materials Technology (Shanghai) Co., Ltd., is changing the implementation method of part of its fundraising projects and adjusting its internal investment structure to enhance operational efficiency and marketing effectiveness [5][8]. Fundraising Overview - The company successfully issued 27,000,000 shares at a price of RMB 58.08 per share, raising a total of RMB 1,568,160,000. After deducting underwriting fees and other expenses, the net amount raised was RMB 1,433,768,189.41, with actual funds received amounting to RMB 1,453,525,120 [2][4]. Project Investment Plans - The planned investment projects include: - New annual production of 70,000 tons of high-performance coatings: RMB 43,000,000 - Headquarters and R&D center in Jiading: RMB 15,000,000 - Intelligent warehousing construction: RMB 5,553,470 - Marketing and service network construction: RMB 4,205,510 - Supplementing working capital: RMB 25,000,000 - Total planned investment: RMB 92,758,980 [4][5]. Changes in Project Implementation - The company plans to change the implementation method of the "Marketing and Service Network Construction Project" by canceling domestic and overseas site expenses and equipment purchases, while increasing personnel and travel expenses [6][7]. - The project will focus on establishing regional sales service teams at the headquarters and subsidiary in Zhuhai, rather than setting up fixed marketing points in various regions [6][7]. Reasons for Adjustments - The adjustments are made to improve efficiency and flexibility in marketing and service operations, as the previous plan of establishing fixed points was found to be limiting [6][7]. - The company will utilize its own funds for overseas sales activities instead of relying on raised funds due to challenges in cross-border payments and regulatory compliance [7]. Impact of Changes - The changes do not alter the total amount of fundraising or the intended use of funds, ensuring that shareholder interests are not compromised [8][9]. - The adjustments are expected to enhance the efficiency of fund usage and align with the company's strategic development goals [8][9]. Approval Process - The adjustments were approved by the company's board on August 20, 2025, and will be submitted for shareholder approval [9]. Sponsor's Verification Opinion - The sponsor, UBS Securities, has reviewed the changes and found them compliant with relevant regulations, confirming that the adjustments will not affect the normal execution of the fundraising investment plan [9].
奥雅股份: 光大证券股份有限公司关于深圳奥雅设计股份有限公司暂时调整募投项目部分场地用途的核查意见
Zheng Quan Zhi Xing· 2025-08-19 09:14
光大证券股份有限公司 关于深圳奥雅设计股份有限公司 暂时调整募投项目部分场地用途的核查意见 光大证券股份有限公司(以下简称"光大证券"、"保荐机构")作为深圳奥 雅设计股份有限公司(以下简称"奥雅股份"、"公司"或"发行人")首次公开 发行股票并在创业板上市的保荐机构,根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关规定,经审慎核查,就奥雅股份 暂时调整募投项目部分场地用途的事项进行审慎核查,核查情况及具体核查意见 如下: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意深圳奥雅设计股份有限公司首次公开 发行股票注册的批复》(证监许可〔2021〕275 号)同意注册,奥雅股份首次公 开发行人民币普通股(A股)股票 15,000,000 股,每股面值 1 元,每股发行价格 为人民币 54.23 元,募集资金总额为人民币 813,450,000.00 元,扣除相关发行费 用人民币 98,856,094.35 元(不含税),实际募集资金净额为 714,593,905.65 元(含 超募资金 11,27 ...
西高院: 西高院2025年第二次临时股东大会会议资料
Zheng Quan Zhi Xing· 2025-07-03 16:05
Core Viewpoint - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss two main proposals: changing the implementation subjects and locations of certain fundraising projects, and expanding the company's business scope while amending its articles of association [1][13]. Group 1: Proposal on Changing Implementation Subjects and Locations - The company plans to change the implementation subjects and locations of certain fundraising projects to enhance the efficiency of fund usage and align with its strategic planning and business needs [6][10]. - The total investment amount for the fundraising projects will remain unchanged, and there will be no adverse impact on the fundraising projects or shareholder interests [12]. - The new implementation subject will be Xigao Institute (Xiamen) Electric Research Institute Co., Ltd., which is positioned as a new R&D institution with testing service capabilities [11][12]. Group 2: Proposal on Expanding Business Scope and Amending Articles of Association - The company intends to expand its business scope to include manufacturing and sales of testing machines and experimental analysis instruments, among other activities [13][14]. - The amendments to the articles of association will reflect the expanded business scope, ensuring compliance with regulatory requirements [15]. - The company seeks authorization from the shareholders to handle the necessary business registration changes related to the amendments [15].